High-dose isoniazid is recommended to treat multidrug-resistant tuberculosis (MDR TB). Among 958 MDR TB isolates identified in France during 2008-2022, 93.1% exhibited high-level isoniazid resistance, and molecular testing showed limited diagnostic accuracy in predicting resistance. Clinicians should reconsider using high-dose isoniazid in MDR TB treatment because of suboptimal effect and toxicity concerns.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11878312 | PMC |
| http://dx.doi.org/10.3201/eid3103.241473 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High-dose isoniazid is recommended to treat multidrug-resistant tuberculosis (MDR TB). Among 958 MDR TB isolates identified in France during 2008-2022, 93.1% exhibited high-level isoniazid resistance, and molecular testing showed limited diagnostic accuracy in predicting resistance.
View Article and Find Full Text PDFDevelopment and validation of BCG vaccine-induced novel granulomatous liver injury preclinical animal model.
Animal Model Exp Med
February 2025
Department of Pharmacology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Background: Developing a granulomatous liver injury preclinical model may pave the way to understanding hepatic-TB (tuberculosis) and autoimmune granulomatous liver diseases. Antitubercular (ATT) and other drugs' metabolism in the presence of a specific type of liver injury is not well understood. The present study aimed to establish a preclinical model of granulomatous hepatitis by using the BCG (Bacillus Calmette-Guérin) vaccine, further studying it in the presence of ATT dosing, and analyze the pharmacokinetics of isoniazid, rifampicin, and their respective primary metabolites.
View Article and Find Full Text PDFExcipient-free inhalable combination shell-core microparticles with clofazimine as shell for extended pulmonary retention of isoniazid in core.
Int J Pharm
March 2025
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Kolkata 700054 India. Electronic address:
Pulmonary delivery of combination anti-tubercular drugs can prevent emergence of drug resistance and improve therapeutic efficacy. However, several drugs in anti-Tuberculosis combinations possess contrasting physicochemical properties that necessitate precise particle engineering with meticulous design for successful co-delivery. High dose requirements further constrain addition of excipients in the formulation.
View Article and Find Full Text PDFThe role of isoniazid dosage and NAT2 gene polymorphism in the treatment of tuberculous meningitis.
Front Immunol
February 2025
Department of Respiratory and Critical Care Medicine, Zhejiang Provincial People's Hospital Bijie Hospital, Bijie, Guizhou, China.
Background: Tuberculous meningitis (TBM) is a non-purulent inflammatory condition affecting the meninges and spinal membranes, caused by Mycobacterium tuberculosis (MTB) infection. This study seeks to explore the impact of varying INH dosages and NAT2 gene polymorphisms on TBM treatment, contributing new insights to improve clinical management and patient prognosis.
Methods: Patients with TBM hospitalized between July 2020 and December 2022 were categorized into two groups based on INH dosage: the standard-dose group (300 mg/day) and the high-dose group (600 mg/day).
BMI as a predictor of progression from TB infection to active TB in PLHIV.
Int J Tuberc Lung Dis
February 2025
Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique;, ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain;, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Barcelona, Spain.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!